138 related articles for article (PubMed ID: 29400000)
1. Correlation analysis of mesenchymal-epithelial transition factor protein and human epidermal growth receptor 2 protein expression in 1479 cases of lung adenocarcinoma in China.
Yang L; Che Y; Guo L; Zheng B; Wang B; Yang Z; Zhu Y; Li J
Thorac Cancer; 2018 Apr; 9(4):439-444. PubMed ID: 29400000
[TBL] [Abstract][Full Text] [Related]
2. Identification of Tyrosine-Phosphorylated Proteins Upregulated during Epithelial-Mesenchymal Transition Induced with TGF-β.
Okayama A; Miyagi Y; Oshita F; Ito H; Nakayama H; Nishi M; Kurata Y; Kimura Y; Ryo A; Hirano H
J Proteome Res; 2015 Oct; 14(10):4127-36. PubMed ID: 26216473
[TBL] [Abstract][Full Text] [Related]
3. ROS-1 re-arrangements and c-MET amplifications in adenocarcinoma lung: A tertiary care center study from North India.
Shukla S; Pandey RK; Kant S; Garg R; Husain N
Indian J Pathol Microbiol; 2019; 62(3):433-436. PubMed ID: 31361233
[TBL] [Abstract][Full Text] [Related]
4. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
5. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
Qin RY; Liu LS; Zhang HY; Lu CH; Guo XY; Zhang LY; Yuan XB; Xue HH
Medicine (Baltimore); 2021 Jan; 100(4):e24300. PubMed ID: 33530219
[TBL] [Abstract][Full Text] [Related]
6. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Han K; Zhang Y
J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
[TBL] [Abstract][Full Text] [Related]
7. Protein overexpression and gene amplification of cellular mesenchymal-epithelial transition factor is associated with poor prognosis in micropapillary-predominant subtype pulmonary adenocarcinoma.
Zhang J; Sun J; Zhang Z; Liang X; Luo Y; Wu S; Liang Z
Hum Pathol; 2018 Feb; 72():59-65. PubMed ID: 29128478
[TBL] [Abstract][Full Text] [Related]
8. High Expression of BCAR1 by Circulating Tumor Cells and Tumor Tissues Is Predictive of a Poor Prognosis of Early-Stage Lung Adenocarcinoma Potentially Due to Regulation of Epithelial-Mesenchymal Transition.
Jiang S; Mao C; Jiang B; Tan Q; Deng B
Technol Cancer Res Treat; 2020; 19():1533033820983086. PubMed ID: 33334252
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of the co-expression of EGFR and HER2 in adenocarcinoma of the uterine cervix.
Ueda A; Takasawa A; Akimoto T; Takasawa K; Aoyama T; Ino Y; Nojima M; Ono Y; Murata M; Osanai M; Hasegawa T; Saito T; Sawada N
PLoS One; 2017; 12(8):e0184123. PubMed ID: 28859123
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
[TBL] [Abstract][Full Text] [Related]
11. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE
J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal-epithelial transition gene amplification and protein overexpression in stage IV pulmonary adenocarcinoma.
Ando R; Fujino M; Kominami-Kiriyama A; Ito A; Koide T; Ito M
Jpn J Clin Oncol; 2019 Aug; 49(8):755-761. PubMed ID: 31329925
[TBL] [Abstract][Full Text] [Related]
13. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
[TBL] [Abstract][Full Text] [Related]
14. HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1.
Kumagai T; Tomita Y; Nakatsuka SI; Kimura M; Kunimasa K; Inoue T; Tamiya M; Nishino K; Susaki Y; Kusu T; Tokunaga T; Okami J; Higashiyama M; Imamura F
Thorac Cancer; 2018 Apr; 9(4):466-471. PubMed ID: 29473311
[TBL] [Abstract][Full Text] [Related]
15. Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.
Pan Y; Zhang Y; Ye T; Zhao Y; Gao Z; Yuan H; Zheng D; Zheng S; Li H; Li Y; Jin Y; Sun Y; Chen H
J Thorac Oncol; 2019 Nov; 14(11):2003-2008. PubMed ID: 31382039
[TBL] [Abstract][Full Text] [Related]
16. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
Onozato R; Kosaka T; Kuwano H; Sekido Y; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
Gow CH; Hsieh MS; Wu SG; Shih JY
Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
[TBL] [Abstract][Full Text] [Related]
18. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas.
Augustin J; Gabignon C; Scriva A; Menu L; Calmel C; Scatton O; Paye F; Fléjou JF; Praz F; Cervera P; Wendum D
Virchows Arch; 2020 Jul; 477(1):33-45. PubMed ID: 32447492
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and therapeutic ERβ, HER2, BRCA biomakers in the histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification.
Zhong L; Zhang C; Jia W; Zhang P
Ann Diagn Pathol; 2021 Apr; 51():151700. PubMed ID: 33465722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
